Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug GW433908, a formulation that substantially reduces the number of tablets per dose compared with ampren...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Wood, Robin, Arasteh, Keikawus, Stellbrink, Hans-Jürgen, Teofilo, Eugenio, Raffi, François, Pollard, Richard B., Eron, Joseph, Yeo, Jane, Millard, Judith, Wire, Mary Beth, Naderer, Odin J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2004
Aiheet:
Antiviral Agents
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC310156/
https://ncbi.nlm.nih.gov/pubmed/14693528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.1.116-123.2004
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia